Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107912 · ClinicalTrials.gov registry record · Phase 1
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
NCT01107912 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 155 participants.
The verdict
NCT01107912, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
Study Summary
The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
Interventions
- DRUG clopidogrel
- DRUG prasugrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01107912
The ClinicalTrials.gov registry entry for NCT01107912 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which clopidogrel is the first listed.
NCT01107912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01107912 about?
NCT01107912 is a clinical study titled "Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease". The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
What is the current status of trial NCT01107912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2010-03. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01107912?
The interventions under investigation include: clopidogrel (DRUG), prasugrel (DRUG).
Who is sponsoring clinical trial NCT01107912?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.